suggesting the need to move rapidly to trials testing combination therapies. Another concern is the relatively high incidence of cutaneous malignancies in patients treated with BRAFV600E inhibitors along with other cutaneous adverse effects. The report of a patient on both BRAF and MEK inhibitors who developed a RAS-mutated pancreatic cancer deepens the need to study novel treatment approaches on carefully monitored clinical trials. 10 There also remains the intriguing question of why some patients with BRAFV600E somatic, activating mutations of a hematopoietic lineage develop ECD vs LCH vs hairy cell leukemia. Is the cell context or maturational stage key to this question? And if the mutations arise in a similar precursor, what other factors direct the aberrant cell along such different neoplastic paths? Clearly, more work will be necessary and that work will require standardized diagnostic and response criteria. Such goals will also need to be applied to other histiocytic disorders, such as juvenile xanthogranulomatous disease and Rosai-Dorfman disease.
High aerial acts without a net are dangerous, but attract audiences. Bringing more attention to rare diseases like ECD will hopefully serve a similar purpose.
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In this issue of Blood, Cheng and colleagues report first on intriguingly complex pre-messenger RNA (pre-mRNA) global alternate splicing (AS) events that occur in primary erythroblasts. Predominant regulatory roles then are implicated for a Muscleblind-like (MBNL) splicing factor, Mbnl1 (an AS regulator in pluripotent embryonic stem [ES] cells and myoblasts), and for nuclear distribution element like-1 (Ndel1) as a Mbnl1 target. Via loss-of-function (LOF) analyses, Mbnl1 and Ndel1 further are evidenced to support erythroblast development. 1 E diting of primary gene transcripts to yield variant exon-included vs -excluded mRNA forms is an important mechanism for generating protein isoforms with diversified activities. 2 To illustrate, one established hematologic example of such AS is FAS in which exon-6 inclusion yields a membraneanchored proapoptotic ligand, whereas exon-6 excision generates soluble apoptosis antigen-1 with prosurvival properties. 3 In higher eukaryotes, the majority of transcripts may, in fact, be subject to AS, 2 a process which is regulated by one of the most sophisticated of subcellular machines, the spliceosome (snRNPs U1-U6, plus ;200 polypeptides). 4 In leukemogenic contexts, heightened attention to the spliceosome recently has arisen from associated newly discovered mutations, especially a SF3B1 component. Specifically, SF3B1 is mutated at substantially heightened frequencies in both myelodysplastic syndrome and chronic lymphocytic leukemia. 4 Muscleblind is an AS factor that is involved in selective programs of splicing decisions (and was discovered in Drosophila as a regulator of muscle) and photoreceptor differentiation. 6 Overall, work by Cheng et al provides novel insight into global AS events during erythropoiesis, and specifically so in murine fetal liver erythroid progenitors as a robust model system. 1 Selective utilization of splicing regulators that target specific sets of AS events also is implicated, with Mbnl1 and Ndel1 as initially defined players. Among Mbnl1-3, additional roles for Mbnl2 in adult bone marrow erythropoiesis will be of interest to define in future studies. For Ndel1, possible effects on erythroblast growth, cytoskeletal features, and/or differentiation also merit extended attention. In a broader scope, RNAseq analyses also have been recently reported for developing human (pro)erythroblasts, 10 and such contributions should enable further insight into AS regulation, specificity, and function during normal and dysregulated human erythropoiesis. Conflict-of-interest disclosure: The author declares no competing financial interests. Platelets as pivot in the antiphospholipid syndrome
In this issue of Blood, Proulle et al demonstrate that platelets are essential for the prothrombotic effects of anti-b 2 -glycoprotein I autoantibodies in a mouse model of the antiphospholipid syndrome (APS).
1
A PS is characterized by the presence of antiphospholipid antibodies in patients with thrombosis or pregnancy morbidity. 2 Although its name suggests otherwise, antiphospholipid antibodies are not directed against phospholipids but toward plasma proteins with affinity for anionic phospholipids. Experiments in a mouse model for APS have shown that autoantibodies against the plasma protein b 2 -glycoprotein I are responsible for the increased risk of thrombosis. A complication in our understanding of the syndrome is that no physiological function has been assigned to b 2 -glycoprotein I and that men and mice without b 2 -glycoprotein I seem to be healthy. 3 How antibodies directed against b 2 -glycoprotein I can lead to an increased risk of thrombotic complications is unsolved and the cause of vivacious debates. A consensus now is that the autoantibodies induce a new activity for the protein. It has been shown that b 2 -glycoprotein I antibody complexes, but not b 2 -glycoprotein I alone, can activate different cell types that are involved in the regulation of hemostatic response, resulting in a prothrombotic state. A major question that remains is: "What are the target cells in vivo for the antibodyb 2 -glycoprotein I complexes?" b 2 -glycoprotein I can exist in 2 completely different conformations. 4 In plasma, it is present as a circular protein in which its N-terminal domain interacts with its C-terminal domain. After interaction with antibodies, the protein opens up and forms a hockey stick-like conformation. This stretched conformation now expresses a hidden epitope in its C-terminal domain that is involved in the binding of the antibody-b 2 -glycoprotein I complex to cells. To complicate matters, this complex is very sticky and binds in vitro to many different proteins and cellular receptors, questioning the value of the results of these experiments. Animal experiments are an essential tool to understand the consequences of cellular interactions of the autoantibodiesb 2 -glycoprotein I complexes. However, mouse models of APS have shown that endothelial cells, monocytes, and platelets all became activated when anti-b 2 -glycoprotein I antibodies were infused. 5 The question remains whether 1 specific cell is the prime target or that the complexes can activate different cell types independently of each other. The experiments of Proulle et al showed that inhibition of platelet activation prevents the activation of endothelial cells. Thus platelets are the first target for the complexes, and products released from activated platelets are responsible for the local activation of endothelial cells.
